为激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌选择一线细胞周期蛋白依赖性激酶4/6抑制剂的困境
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.
作者信息
Grinshpun Albert, Tolaney Sara M, Burstein Harold J, Jeselsohn Rinath, Mayer Erica L
机构信息
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
出版信息
NPJ Breast Cancer. 2023 Mar 22;9(1):15. doi: 10.1038/s41523-023-00520-7.
Abstract
The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the first-line setting for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Randomized trials have demonstrated similar and significant improvements in progression-free survival using the three available CDK4/6 inhibitors and led to regulatory approval. However, mature overall survival data now suggest potential differences among the various agents, suggesting an evolution in selection preferences.
摘要
对于激素受体阳性、人表皮生长因子受体2阴性的转移性乳腺癌患者，内分泌药物与细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂联合使用是一线治疗的标准方案。随机试验表明，使用三种可用的CDK4/6抑制剂在无进展生存期方面有相似且显著的改善，并获得了监管部门的批准。然而，目前成熟的总生存期数据表明，不同药物之间可能存在差异，这表明选择偏好发生了变化。
相似文献
1
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.为激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌选择一线细胞周期蛋白依赖性激酶4/6抑制剂的困境
NPJ Breast Cancer. 2023 Mar 22;9(1):15. doi: 10.1038/s41523-023-00520-7.
2
Case report: F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient.病例报告：在一名激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌患者中，氟-18氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（F-FES PET/CT）预测了一线细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂治疗疾病进展后二线和三线CDK4/6抑制剂的治疗反应。
Front Oncol. 2022 Dec 23;12:1095779. doi: 10.3389/fonc.2022.1095779. eCollection 2022.
3
Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.帕博西尼及其他 CDK4/6 抑制剂在激素受体阳性人表皮生长因子受体 2 阴性转移性乳腺癌治疗中的应用：亚太视角和 CDK4/6 抑制剂使用的实用管理指南。
Curr Med Res Opin. 2020 Aug;36(8):1363-1373. doi: 10.1080/03007995.2020.1783646. Epub 2020 Jul 2.
4
CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care.CDK4/6 抑制剂联合内分泌治疗激素受体阳性、HER2 阴性转移性乳腺癌：新的标准治疗。
Asia Pac J Clin Oncol. 2021 Jan;17 Suppl 1:3-14. doi: 10.1111/ajco.13555.
5
Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.CDK4/6抑制剂联合内分泌治疗晚期激素受体阳性（HR+）和人表皮生长因子受体2阴性（HER2-）乳腺癌的药物经济学评价：一项系统综述
Ann Transl Med. 2022 Feb;10(4):233. doi: 10.21037/atm-21-5110.
6
Prognostic Significance of Low HER2 Expression in Patients With Metastatic Hormone Receptor-positive Breast Cancer Treated With First Line CDK4/6 Inhibitors: A Greek Multicenter Real-world Data Analysis.一线 CDK4/6 抑制剂治疗的转移性激素受体阳性乳腺癌患者中低 HER2 表达的预后意义：一项希腊多中心真实世界数据分析
Cancer Diagn Progn. 2022 Sep 3;2(5):585-591. doi: 10.21873/cdp.10146. eCollection 2022 Sep-Oct.
7
Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.选择 CDK4/6 抑制剂在激素受体阳性晚期乳腺癌中的最佳位置-SONIA 研究：一项随机对照试验的研究方案。
BMC Cancer. 2018 Nov 20;18(1):1146. doi: 10.1186/s12885-018-4978-1.
8
Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.在 CDK4/6 抑制剂治疗进展后，基于 tucidinostat 的治疗在激素受体阳性、预处理广泛的转移性乳腺癌中的临床结局。
Breast. 2022 Dec;66:255-261. doi: 10.1016/j.breast.2022.10.018. Epub 2022 Nov 2.
9
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.乳腺癌中的CDK4/6抑制剂：超越激素受体阳性、人表皮生长因子受体2阴性疾病
Ther Adv Med Oncol. 2018 Dec 17;10:1758835918818346. doi: 10.1177/1758835918818346. eCollection 2018.
10
Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?序贯内分泌治疗转移性乳腺癌：在 CDK4/6 抑制剂治疗进展后我们该怎么做？
Curr Oncol Rep. 2020 May 16;22(6):57. doi: 10.1007/s11912-020-00917-8.
引用本文的文献
1
Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe.欧洲HR+/HER2-晚期乳腺癌患者一线哌柏西利与芳香化酶抑制剂治疗的真实世界临床结局
Breast Cancer Res Treat. 2025 Aug 6. doi: 10.1007/s10549-025-07707-5.
2
Unlocking Cellular Memory and Gene Regulatory Networks: Pioneering the Future of Therapeutic Innovations.解锁细胞记忆与基因调控网络：开创治疗创新的未来。
Cells. 2025 Jun 14;14(12):903. doi: 10.3390/cells14120903.
3
Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.PARSIFAL试验中，哌柏西利联合氟维司群或来曲唑用于内分泌敏感、激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的延长随访。
ESMO Open. 2025 Jun 17;10(7):105309. doi: 10.1016/j.esmoop.2025.105309.
4
Cell cycle proteins: Linking the cell cycle to tumors.细胞周期蛋白：连接细胞周期与肿瘤
Oncol Res. 2025 May 29;33(6):1335-1346. doi: 10.32604/or.2025.058760. eCollection 2025.
5
Continuing Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Advanced Breast Cancer: A Meta-Analysis.晚期乳腺癌病情进展后继续使用细胞周期蛋白依赖性激酶4/6抑制剂：一项荟萃分析
Cancers (Basel). 2025 May 9;17(10):1609. doi: 10.3390/cancers17101609.
6
Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2- Metastatic Breast Cancer.帕博西尼、阿贝西利和瑞博西利在激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌患者中的医疗资源利用及成本比较
Clinicoecon Outcomes Res. 2025 Mar 26;17:247-264. doi: 10.2147/CEOR.S496100. eCollection 2025.
7
Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer.原发性雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌中富含人表皮生长因子受体2的内在分子亚型的基因组特征分析
Nat Commun. 2025 Mar 5;16(1):2208. doi: 10.1038/s41467-025-57419-z.
8
TFF3 facilitates dormancy of anti-estrogen treated ER+ mammary carcinoma.三叶因子3（TFF3）促进抗雌激素治疗的雌激素受体阳性（ER+）乳腺癌的休眠。
Commun Med (Lond). 2025 Feb 21;5(1):45. doi: 10.1038/s43856-024-00710-9.
9
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer.推进治疗选择：HR+/HER2-转移性乳腺癌中的CDK4/6抑制剂转换
Breast. 2025 Feb;79:103875. doi: 10.1016/j.breast.2025.103875. Epub 2025 Jan 10.
10
Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer.CDK 4/6抑制剂在雌激素受体阳性转移性乳腺癌中的真实世界疗效
BJC Rep. 2024 Jun 20;2(1):44. doi: 10.1038/s44276-024-00070-w.
本文引用的文献
1
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.阿贝西利联合内分泌治疗激素受体阳性、HER2 阴性、淋巴结阳性、高危早期乳腺癌（monarchE）：一项随机、开放标签、III 期临床试验的预先计划的中期分析结果。
Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6.
2
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.哌柏西利联合芳香化酶抑制剂治疗激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌的总生存的真实世界研究
NPJ Breast Cancer. 2022 Oct 11;8(1):114. doi: 10.1038/s41523-022-00479-x.
3
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.瑞博西林联合来曲唑治疗晚期乳腺癌的总生存期。
N Engl J Med. 2022 Mar 10;386(10):942-950. doi: 10.1056/NEJMoa2114663.
4
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer.激素受体阳性乳腺癌治疗中对CDK4/6抑制剂反应和耐药的细胞机制。
Breast Cancer Res. 2022 Mar 5;24(1):17. doi: 10.1186/s13058-022-01510-6.
5
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).帕博西尼联合辅助内分泌治疗激素受体阳性/人表皮生长因子受体 2 阴性早期乳腺癌的 PALbociclib 合作辅助研究中的治疗暴露和停药（PALLAS/AFT-05/ABCSG-42/BIG-14-03）。
J Clin Oncol. 2022 Feb 10;40(5):449-458. doi: 10.1200/JCO.21.01918. Epub 2022 Jan 7.
6
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.MONALEESA-7 试验：绝经前和围绝经期 HR+/HER2-晚期乳腺癌患者中，瑞博西利联合内分泌治疗对比内分泌治疗的更新总生存期：一项 III 期随机临床试验。
Clin Cancer Res. 2022 Mar 1;28(5):851-859. doi: 10.1158/1078-0432.CCR-21-3032.
7
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.CDK4/6抑制剂在乳腺癌中的临床及药理学差异
Front Oncol. 2021 Jul 12;11:693104. doi: 10.3389/fonc.2021.693104. eCollection 2021.
8
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.在 MONALEESA-3 期随机对照试验中，对于激素受体阳性、人表皮生长因子受体 2 阴性的绝经后妇女的晚期乳腺癌，来曲唑联合氟维司群治疗：更新的总生存数据。
Ann Oncol. 2021 Aug;32(8):1015-1024. doi: 10.1016/j.annonc.2021.05.353. Epub 2021 Jun 5.
9
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.帕博西尼用于残留高危侵袭性 HR 阳性和 HER2 阴性早期乳腺癌 - Penelope-B 试验。
J Clin Oncol. 2021 May 10;39(14):1518-1530. doi: 10.1200/JCO.20.03639. Epub 2021 Apr 1.
10
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.在真实世界的美国临床实践中，一线哌柏西利联合来曲唑对比来曲唑单药治疗 HR+/HER2-转移性乳腺癌的疗效比较。
Breast Cancer Res. 2021 Mar 24;23(1):37. doi: 10.1186/s13058-021-01409-8.
Zotero 插件